QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 22 January 2008
doi: 10.1242/jcs.022343

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jcs.022343v1 121/4/450    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Efklidou, S. Articles by Collins, M. K. PubMed PubMed Citation Articles by Efklidou, S. Articles by Collins, M. K.

vFLIP from KSHV inhibits anoikis of primary endothelial cells

Infection and Immunity, University College London, Windeyer Building, 46 Cleveland Street, London W1T 4JF, UK

^* Author for correspondence (e-mail: mary.collins{at}ucl.ac.uk)

Accepted 19 November 2007

Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) infection of endothelial cells is an early event in the aetiology of the endothelial cell tumour Kaposi's sarcoma (KS). We have examined the effect of the KSHV latent protein viral FLICE-like inhibitory protein (vFLIP) on dermal microvascular endothelial cell (MVEC) survival as vFLIP is expressed in the KSHV-infected cells within KS lesions. To do this, we have used a lentiviral vector to express vFLIP in MVECs in the absence of other KSHV proteins. vFLIP activates the classical NF-B pathway in MVECs and causes nuclear translocation of RelA/p65. This NF-B activation prevents detachment-induced apoptosis (anoikis) of MVECs but does not inhibit apoptosis induced by removal of essential survival factors, including vascular endothelial growth factor (VEGF). vFLIP expression inhibits anoikis in part by inducing the secretion of an additional paracrine survival factor(s). The implications of these results for KS development are discussed.

Key words: vFLIP, Anoikis, NF-B, Endothelial cell